302 related articles for article (PubMed ID: 24669014)
1. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
2. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
[TBL] [Abstract][Full Text] [Related]
3. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
[TBL] [Abstract][Full Text] [Related]
4. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
5. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
Zhao TC; Zhou ZH; Ju WT; Liang SY; Tang X; Zhu DW; Zhang ZY; Zhong LP
Cancer Sci; 2022 Feb; 113(2):478-488. PubMed ID: 34826159
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
9. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
[TBL] [Abstract][Full Text] [Related]
10. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
11. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor 15 as a radiation-induced marker in oral carcinoma increasing radiation resistance.
Schiegnitz E; Kämmerer PW; Rode K; Schorn T; Brieger J; Al-Nawas B
J Oral Pathol Med; 2016 Jan; 45(1):63-9. PubMed ID: 25880686
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
17. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.
Hu YJ; Sun WW; Zhao TC; Liu Y; Zhu DW; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2020 Nov; 20(5):154. PubMed ID: 32934722
[TBL] [Abstract][Full Text] [Related]
19. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
[TBL] [Abstract][Full Text] [Related]
20. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]